Thursday, November 21, 2024
Home Tags PP Defence Therapeutics

PP Defence Therapeutics Related News

Defence Therapeutics welcomes Dr Svetlana Selivanova to board of directors

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in radiopharmaceuticals, antibody-drug conjugates (ADC), and immune-oncology vaccines, has announced that Dr Svetlana Selivanova has joined...

Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval

Defence Therapeutics Inc. has announced a significant milestone in its radio-immuno-conjugates project. The Canadian Nuclear Research Initiative Health (CNRI-H) Program application by Defence Therapeutics has...
Accum™

Defence Receives No Objection Letter from Health Canada for Phase I Trial of ACCUM-002...

Defence Therapeutics receives a no objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients...
DEFENCE’s ARM-X vaccine completely inhibits ovarian cancer growth in treated animals

Defence’s ARM-X vaccine completely inhibits ovarian cancer growth in treated animals

Defence Therapeutics Inc., a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer...

Defence Therapeutics’ AccuTOX® study published in the Journal of Translational Medicine

Defence Therapeutics has announced the publication of a peer-reviewed study on the anti-cancer properties of its unconjugated AccuTOX®.
ARM-002TM vaccine shows effectiveness against pancreatic cancer

Trial demonstrates ARM-002TM vaccine’s effectiveness against pancreatic cancer

Defence Therapeutics has announced a successful pre-clinical vaccination trial utilising its ARM-002TM vaccine against pancreatic cancer.
anti-cancer vaccine

ARM-002TM anti-cancer vaccine shows promise in combatting pre-established melanoma

Defence Therapeutics Inc. has unveiled the exceptional efficacy of its second-generation ARMTM anti-cancer vaccine. The anti-cancer vaccine, dubbed ARM-002TM, has demonstrated proficiency in combating pre-established...
cancer vaccine

Defence Therapeutics announces successful ARM-002TM cancer vaccine results

Defence Therapeutics has announced the successful testing of its second-generation anti-cancer vaccine, named ARM-002TM, utilising its flagship anti-cancer molecule, AccuTOX®. The ARM-002TM cancer vaccine, when...
AccuTOX®

Defence Therapeutics granted US patent for AccuTOX® technology

Defence Therapeutics has achieved a significant milestone with the granting of US patent no. 11,890,350 ('350) by the United States Patent and Trademark Office...
lung tumours

Defence Therapeutics’ breakthrough in cancer treatment: AccuTOX® shows promise against lung tumours

Defence Therapeutics has announced the successful testing of a new formulation of its ACCUM-002TM Dimer CDCA-SV40 against lung tumours.
FDA approval

Defence Therapeutics granted FDA approval for Phase I Clinical Trial of AccuTOX®

Defence Therapeutics has announced a pivotal milestone: the U.S. Food and Drug Administration (FDA) has granted a green light with a "Study May Proceed"...
AccuTOX®

Defence Therapeutics applies to use AccuTOX® as an advanced tumour treatment

Defence Therapeutics has submitted an Investigational New Drug application for AccuTOX®, an injectable anticancer molecule.
vaccine technology

Defence Therapeutics awarded CIPO patent for vaccine technology

Defence Therapeutics has announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for the company's Canadian patent application no....
AccuTOX®

AccuTOX® anticancer drug demonstrates exciting antigen cross-presentation

Defence Therapeutics Inc., a prominent Canadian biopharmaceutical company renowned for its work in immune-oncology vaccines and drug delivery technologies, has announced the discovery of...

Administration of AccuTOX™-chitosan inhibits the growth of established solid lymphoma in animals

Defence Therapeutics has announced that systemic administration of novel AccuTOX™-chitosan encapsulated formulation inhibits the growth of pre-established solid lymphoma resulting in their progressive shrinking...

Defence Therapeutics Inc. releases Accum® study revealing its anti-cancer properties

Defence Therapeutics Inc. have announced the publication of a peer-reviewed study on the anti-cancer properties of its unconjugated Accum®.
lipid nanoparticles

Accum®-mRNA lipid nanoparticles have double the antibody response of traditional mRNA vaccines

Defence Therapeutics has announced a groundbreaking achievement, demonstrating that its Accum®-mRNA lipid nanoparticles elicit twice the antibody response of mRNA-based vaccines. The company's encapsulation strategy,...
Accum® technology

How Defence’s Accum® technology is advancing cancer therapeutics

Industry-leading biotechnology pioneer Defence Therapeutics details how the company is advancing immune oncology through its revolutionary Accum® technology. Whether using an antibody, cell-based vaccine or...
Viewpoint with Dennis Quaid

Defence Therapeutics’ biotechnology showcased on the Viewpoint with Dennis Quaid

Defence Therapeutics’ revolutionary biotechnology will feature on the television show Viewpoint with Dennis Quaid. Hosted by veteran actor Dennis Quaid, Viewpoint is an educational television...

Defence completes first milestone of Orano collaboration agreement

Defence Therapeutics Inc. has announced that it has successfully reached the first milestone established in the Orano collaboration agreement. The collaboration agreement was entered with...

Pin It on Pinterest